Preprint Article Version 1 Preserved in Portico This version is not peer-reviewed

NanoLuc Binary Technology as a Methodological Approach: An Important New Tool for Studying the Localization of Androgen Receptor and Androgen Receptor Splice Variant V7 Homo- and Heterodimers

Version 1 : Received: 12 April 2023 / Approved: 13 April 2023 / Online: 13 April 2023 (02:54:24 CEST)

A peer-reviewed article of this Preprint also exists.

Guzman, J.; Weigelt, K.; Neumann, A.; Tripal, P.; Schmid, B.; Winter, Z.; Palmisano, R.; Culig, Z.; Cronauer, M.V.; Muschler, P.; et al. NanoLuc Binary Technology as a Methodological Approach: An Important New Tool for Studying the Localization of Androgen Receptor and Androgen Receptor Splice Variant V7 Homo and Heterodimers. BMC Cancer 2024, 24, doi:10.1186/s12885-024-12110-2. Guzman, J.; Weigelt, K.; Neumann, A.; Tripal, P.; Schmid, B.; Winter, Z.; Palmisano, R.; Culig, Z.; Cronauer, M.V.; Muschler, P.; et al. NanoLuc Binary Technology as a Methodological Approach: An Important New Tool for Studying the Localization of Androgen Receptor and Androgen Receptor Splice Variant V7 Homo and Heterodimers. BMC Cancer 2024, 24, doi:10.1186/s12885-024-12110-2.

Abstract

The androgen/androgen receptor (AR)-signaling axis plays a central role in the development and growth of prostate cancer (PCa) cells. Upon androgen-binding the AR dimerizes with another AR, translocates into the nucleus where the AR-dimer activates/inactivates androgen-dependent genes. In consequence treatments for locally advanced or metastatic PCa are commonly based on androgen deprivation therapies (ADT). Unfortunately, the clinical benefits of ADT are only transitory and most tumors develop mechanisms allowing the AR to bypass its need for physiological levels of circulating androgens. In the clinic failure of ADT is often characterized by the synthesis of a C-terminally truncated, constitutively active AR splice variant, termed AR-V7. In contrast to AR, the constitutively active AR-V7 does no longer need androgenic stimuli for nuclear entry and/or dimerization. The goal of the present study was to mechanistically decipher the interaction between full-length AR (AR-FL) and AR-V7 in AR-null HEK-293 cells using the NanoLuc Binary Technology (NanoBiT) structural complementation assay under androgen stimulation and deprivation conditions. Our data point toward a hypothesis that AR-FL/AR-FL homodimers form in the cytoplasm, whereas AR-V7/AR-V7 localize in the nucleus. However, after 15 min of androgen stimulation, all AR-FL/AR-FL, AR-FL/AR-V7 and AR-V7/AR-V7 dimers localized in the nucleus. In this way, we can show an androgen-regulated interaction between AR-FL and AR-V7 at forming heterodimers that localize in the nucleus, whereas AR-V7/AR-V7 dimers were found to localize in the absence of androgens in the nucleus. Treatment with enzalutamide diminished the luminescence of AR-FL homodimers and AR-FL/AR-V7 heterodimers but not AR-V7/AR-V7 homodimers.

Keywords

Androgen receptor; androgen receptor splice variant 7; prostate cancer; localization; NanoBiT

Subject

Medicine and Pharmacology, Urology and Nephrology

Comments (0)

We encourage comments and feedback from a broad range of readers. See criteria for comments and our Diversity statement.

Leave a public comment
Send a private comment to the author(s)
* All users must log in before leaving a comment
Views 0
Downloads 0
Comments 0
Metrics 0


×
Alerts
Notify me about updates to this article or when a peer-reviewed version is published.
We use cookies on our website to ensure you get the best experience.
Read more about our cookies here.